Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.
J Adv Pract Oncol. 2017 Jan-Feb;8(1):44-55
Authors: Armideo E, Callahan C, Madonia L
Abstract Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials.